FiercePharmaOriginal article
{"a":[{"_":"In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national coverage","$":{"href":"/pharma/draft-guidance-uk-cost-arbiter-nice-rebuffs-gileads-twice-year-prep-med-national-coverage","hreflang":"en"}}]}
RegulatoryrejectedlenacapavirNegative
AI Analysis
Summary
NICE has issued draft guidance recommending against NHS coverage of Gilead's twice-yearly PrEP medication lenacapavir, a decision criticized by HIV charities as disappointing.
Outcome Details
NICE draft guidance recommends against coverage on NHS
Importance:7/10
Sentiment:
-0.85
NICEPrEPcoverage decisionNHSlenacapavirHIV
Related Companies
Read the original article
Published by FiercePharma on September 10, 2026 10:14 AM